No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment

Current Medical Research and Opinion

Volumn 19, Issue 8, 2003, Pages 715-717

  Auriacombe, S ^a   Pere, J J ^b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b NOVARTIS PHARMA K K   (Japan)

Author keywords

Alzheimer's disease; Donepezil; Rivastigmine; Switching

Indexed keywords

DONEPEZIL; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; CARBAMATES; FEMALE; HUMANS; INDANS; MALE; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; PHENYLCARBAMATES; PIPERIDINES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0344413675     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125002504     Document Type: Article

References (5)

1. Auriacombe S, Pere J-J, Loria-Kanza Y, Vellas B. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002;18:129-38
2. McRae T, Schwam E. Comments on efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002;18(6):i-iii
3. Auriacombe S, Pere J-J, Rivage Study Group. Response to comments on efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002;18(6):iv-vi
4. Rogers S, Farlow M, Doody R, Mohs R, Friedhoff L. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-45
5. Rogers S, Doody R, Mohs R, Friedhoff L. Donepezil improves cognition and global function in Alzheimer disease. Arch Intern Med 1998;158:1021-31